Form 8-K - Current report:
SEC Accession No. 0001610618-24-000143
Filing Date
2024-11-07
Accepted
2024-11-07 16:13:34
Documents
15
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CIDARA THERAPEUTICS, INC. FORM 8-K cdtx-20241107.htm   iXBRL 8-K 28790
2 EARNINGS RELEASE ex9912024-11x07.htm EX-99.1 80655
6 GRAPHIC cdtxlogoa18a.jpg GRAPHIC 63449
  Complete submission text file 0001610618-24-000143.txt   334402

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20241107.xsd EX-101.SCH 1780
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20241107_lab.xml EX-101.LAB 22804
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20241107_pre.xml EX-101.PRE 13048
17 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20241107_htm.xml XML 2829
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 241435867
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)